These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19554858)

  • 1. Recent legal developments and the authority of the Australian Therapeutic Goods Administration.
    Shirlow E; Faunce T
    J Law Med; 2009 May; 16(5):764-9. PubMed ID: 19554858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.
    Ghosh D; Skinner M; Ferguson LR
    Toxicology; 2006 Apr; 221(1):88-94. PubMed ID: 16481089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
    Chodock R; Yolkut D; Connolly DR
    Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A
    Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation.
    Struve CT
    Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting Factor VIII cases: is it time for an agency adjudication system?
    Su YC
    Food Drug Law J; 2008; 63(4):943-61. PubMed ID: 19601390
    [No Abstract]   [Full Text] [Related]  

  • 10. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 11. Off-label use of medical devices in radiology: regulatory standards and recent developments.
    Smith JJ
    J Am Coll Radiol; 2010; 7(2):115-9. PubMed ID: 20142085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
    Mathis LL; Iyasu S
    Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: how similar or dissimilar are they?
    Roger SD
    Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
    Kelly JJ; David M
    Food Drug Law J; 2009; 64(1):115-48. PubMed ID: 19998743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delays in access to affordable medicines: putting policy into perspective.
    Pearce A; van Gool K; Haywood P; Haas M
    Aust Health Rev; 2012 Nov; 36(4):412-8. PubMed ID: 23062753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Australian and New Zealand governments agree to proceed with the joint regulatory agency for therapeutic products.
    Moore J
    J Law Med; 2011 Dec; 19(2):272-4. PubMed ID: 22320002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.